Please login to the form below

Not currently logged in
Email:
Password:

Catalent appoints two board members

Jack Stahl and Rolf Classon to advise drug development, delivery and supply company
catalent-rolf-classon

Catalent has named two experienced healthcare figures to its board of directors.

Jack Stahl, former CEO of cosmetics firms Revlon, and Rolf Classon, former chairman at Bayer Healthcare, will use to their experience to advise Catalent, a leading player in providing drug development, delivery and supply services to pharma companies.

Stahl headed Revlon from 2002 to 2006 following a stint as chief operating officer at the Coca-Cola Company. He also serves on the Boards of Coty, Delhaize Group, and the US board of advisers of CVC Capital.

Classon served as chairman at Bayer Healthcare from 2002 until 2004 as part of a long career at Bayer that began in 1991. His roles at the German company included a seven-year spell as president of Bayer Diagnostics.

“We welcome both Jack and Rolf to our Board,” said John Chiminski, President and CEO, Catalent. “Both are senior healthcare executives, with a wealth of knowledge and experience within the sector.”

20th August 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...